Experience treatment on your terms with 3-times-a-week COPAXONE® 40 mg.
- Proven effectiveness1
- Demonstrated safety and tolerability profile1
- The #1 prescribed brand for relapsing MS in the US2*
- The Shared Solutions® network of personalized support
Want to find out more about NEW 3-times-a-week COPAXONE® 40 mg from a leading MS expert? CALL AN MS-CERTIFIED NURSE - 1.800.887.8100
TAKE CONTROL WITH PROVEN EFFECTIVENESS
Since the approval of COPAXONE® (glatiramer acetate injection) for relapsing‐remitting MS in 1996, many in the MS community have trusted in its proven effectiveness across 5 large clinical studies. Most recently, 3-times-a-week COPAXONE® 40 mg was studied in the largest pivotal trial ever conducted for COPAXONE®.1
3-times-a-week COPAXONE® 40 mg: Proven to reduce the number of relapses
3-times-a-week COPAXONE® 40 mg reduced the number of relapses by 34% compared to placebo (an inactive substance).
Primary study results
Relapses, also called flare-ups or attacks, can cause new symptoms to occur or make old symptoms worse.
3-times-a-week COPAXONE® 40 mg: Proven to reduce the number of brain lesions1
COPAXONE® 3-times-a-week 40 mg showed a significant cumulative reduction in the underlying disease activity as measured by brain lesions on magnetic resonance imaging (MRI) at 6 and 12 months compared to placebo.
Secondary study results
T2 lesions show areas where the brain tissue has been damaged.
number of new
Secondary study results
T1-enhancing lesions, also known as Gadolinium-enhancing T1 lesions, show areas where brain tissue is currently being attacked.
the local number
Expand Study Details
Take control now. Call Shared Solutions® today at 1-800-887-8100 to find out how you can get started on 3-times-a-week COPAXONE® 40 mg.
STAY THE COURSE WITH A THERAPY YOU TRUST
3-times-a-week COPAXONE® 40 mg offers you a demonstrated safety profile.1 With 3-times-a-week COPAXONE® 40 mg, you can feel confident in your decision to stay committed to your relapsing MS therapy.
Although not fully studied, COPAXONE® has not demonstrated any significant interactions with medications commonly used in MS patients.
This includes combination use with corticosteroids (up to 28 days)
COPAXONE® has not been formally evaluated in combination with interferon beta
COPAXONE® is Pregnancy Category B
There is no evidence of risk in humans.
Animal studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, COPAXONE® should be used in pregnancy only if clearly needed.
If you are pregnant or planning to become pregnant, let your doctor know.
Continue reading, HERE
Call Shared Solutions® today at 1-800-887-8100 to find out how you can feel confident with 3-times-a-week COPAXONE® 40 mg.
STAY THE COURSE WITH A THERAPY THAT FITS YOUR LIFESTYLE